Eli Lilly: positive results for tirzepatide in obesity
(CercleFinance.com) - Eli Lilly announces that detailed results from a phase 3 clinical trial evaluating tirzepatide in obese or overweight adults with weight-related comorbidities, excluding type 2 diabetes, have been published in Nature Medicine and presented simultaneously at ObesityWeek 2023.
F tirzepatide met both primary endpoints for efficacy estimation and regimen estimation, demonstrating superiority over placebo over the 72-week double-blind treatment period.
In this study, people who added tirzepatide to their diet and exercise experienced greater and longer-lasting weight loss than those taking placebo, Lilly said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
F tirzepatide met both primary endpoints for efficacy estimation and regimen estimation, demonstrating superiority over placebo over the 72-week double-blind treatment period.
In this study, people who added tirzepatide to their diet and exercise experienced greater and longer-lasting weight loss than those taking placebo, Lilly said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.